Atopic Dermatitis / Eczema Clinical Trials

Regeneron Protocol R668-AD-1526:A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients ≥12 To 17 – ACTIVE/NOT ENROLLING

  • A Phase III clinical trial investigating a biologic IL-4 inhibitor (dupilumab) in subjects ages 12-17 with moderate to severe atopic dermatitis.
  • A 40-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the safety and efficacy of ABT-494 in adult participants with moderate to severe atopic dermatitis. The participants will be randomized in a 1:1:1:1 ratio to one of four treatment groups.

Regeneron protocol R668-AD-1652: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to 11 Years of Age, With Severe Atopic Dermatitis -CURRENTLY ENROLLING

  •  A Phase III clinical trial investigating a biologic IL-4 inhibitor (dupilumab) in subjects ages ≥6 to 11 years old with severe atopic dermatitis.

Regeneron protocol R668-AD-1434: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to 18 Years of Age With Atopic Dermatitis -ACTIVE/ENROLLING BY INVITATION ONLY

  • A Phase III extension trial for patients ages 6 months to 18 years of age who have previously participated in a clinical trial for dupilumab.

Dermira protocol DRM06-AD01: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial To Evaluate The Efficacy And Safety Of Lebrikizumab In Patients With Moderate-To-Severe Atopic Dermatitis-CURRENTLY ENROLLING

  • A Phase II clinical trial investigating a biologic IL-13 inhibitor for patients 18 years of age or older with moderate to severe atopic dermatitis.

Regeneron protocol R668-AD-1762: A Prospective Observational Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis-CURRENTLY ENROLLING

  • A 5 year observational registry for adult patients who have been newly-prescribed Dupixent (dupilumab) for moderate to severe atopic dermatitis.